Replimune Entered into Clinical Trial Collaboration and Supply Agreement with Incyte to Evaluate RP1 + INCB99280 for Cutaneous Squamous Cell Carcinoma
Shots:
- The companies collaborate to evaluate Replimune’s RP1 (lead oncolytic immunotherapy product candidate) + Incyte’s INCB99280 to initiate the clinical trial in patients with high-risk, resectable CSCC. The trial is expected to initiate in early 2024
- Replimune will supply Incyte with RP1 for the study and share equally in the costs of the study. INCB99280, a potent and selective small molecule oral PD-L1 inhibitor showed promising clinical activity and safety in patients with solid tumors
- Additionally, INCB99280 is being studied in multiple P-II studies as a monotx. and in combination with other antitumor agents
Ref: Businesswire | Image: Incyte
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
